Top NYC, NY Companies With Best Stability & Growth (10,000+)

Strong Revenue Growth: Multiple reports cite record net trading revenues through late 2025 and into Q1 2026 (including a sharp year‑on‑year surge), indicating accelerating top‑line performance. These results are presented as consecutive records, suggesting strong momentum into this year.

Market Expansion: The firm lists 14 offices across North America, Europe, and Asia-Pacific and has added regional leadership in Asia, pointing to an expanding geographic footprint. Ongoing hiring activity across technical and trading infrastructure roles further aligns with capacity scale‑up.

Diversified Revenue Streams: Operations span multiple asset classes and channels, including equities, futures, options, currencies, fixed income, crypto, and U.S. retail equity wholesaling. This breadth indicates revenue sources are not confined to a single product or venue.

Diversified Revenue Streams: The group spans proprietary trading, an agency broker (WEX), and asset management (WAM), with ongoing Rule 606 disclosures at WEX and current 13F filings and multi‑billion regulatory AUM figures for WAM reported by data vendors. Feedback suggests this diversification supports platform stability and cushions performance across different market conditions.

Strong Market Position & Advantage: The firm continues to take on lead‑market‑maker roles (e.g., DPM in DJX daily expirations and PLMM assignments on MIAX) and appears as a destination in institutional routing disclosures, indicating active liquidity provision and connectivity. These signals point to entrenched participation across major options venues.

Innovation-Driven Growth: The company emphasizes continuous investment in low‑latency infrastructure, OMS/EMS platforms, and complex‑options tooling, alongside new product responsibilities such as DJX daily expirations. These actions indicate a technology‑led expansion of capabilities rather than retrenchment.

Strong Revenue Growth: Net revenue is rising steadily across recent periods, with constant-currency figures indicating robust underlying momentum. Guidance indicates continued double‑digit expansion in the near term.

Profitability: EBITDA and margins have improved alongside growth, reflecting operating leverage. Management signals an intention to maintain strong margin levels over the medium term.

Diversified Revenue Streams: Growth is broad‑based across Platforms, Unified Commerce, and Digital, suggesting multiple engines support overall expansion. New capabilities and acquisitions are positioned to reinforce balance across channels and use cases.

Strong Market Position & Advantage: Company disclosures indicate a new all‑time high in global trading‑volume market share in Q1 2026 despite industry volumes declining. Management attributes this to gains across spot and derivatives.

Diversified Revenue Streams: Investor materials highlight significant growth in non‑trading revenue, including stablecoin‑related income, with subscriptions and services rising sharply versus the last cycle’s peak. This points to a more balanced business mix beyond transaction fees.

Product Line Growth: Management reports materially increased derivatives share in 2025 with continued momentum in early 2026. Newer offerings such as derivatives and prediction markets are scaling quickly according to the provided materials.

Strong Revenue Growth: Recent quarterly results and a raised full‑year outlook indicate sustained top‑line expansion with momentum exceeding earlier expectations. Feedback suggests a growing demand pipeline and subscription strength are reinforcing this trajectory.

Healthy Cash Flow: Recent quarters delivered strong free cash flow alongside improved operating performance, signaling solid cash generation while scaling. This pattern points to better cash conversion even as the company continues to invest.

Innovation-Driven Growth: Ongoing AI‑related feature releases and partnerships (including vector search, embeddings, and LangChain) position the platform to capture emerging AI workloads. Management’s positioning of Atlas as a data layer for AI adds a secular growth catalyst.

Profitability: Profitability is supported by strong adjusted EBITDA margins, with 2025 at roughly one‑third of revenue and Q1 2026 near that level as tighter cost control held despite mix shifts. This indicates stable profit generation during a transition toward newer businesses.

Product Line Growth: Product lines tied to Pharma Direct and condition‑specific subscriptions are expanding rapidly, with Pharma Direct accelerating year over year and subscriptions returning to growth in Q1 2026. This momentum reflects successful scaling of newer offerings like GLP‑1 weight‑loss programs.

Diversified Revenue Streams: The business is leaning into Pharma Direct and rebuilding subscriptions to offset softness in core prescription transactions over time. Management explicitly positioned Pharma Direct as central to future growth, broadening the mix beyond discount‑card transactions.

Market Expansion: Public materials describe broadened operations across major U.S. hubs and international cities, with additional California expansion plans noted in March 2026 coverage. Company channels also reference global pickup coverage across North America, EMEA, and APJ.

Product Line Growth: Recent updates highlight expanded Device Retrievals and a unified, enterprise‑grade lifecycle platform. These feature additions indicate ongoing investment to address a wider range of assets and workflows.

Strong Hiring & Retention: Active recruitment for senior go‑to‑market roles and an updated headcount listing (e.g., 120 employees on Built In in June 2026) signal team expansion. Job descriptions and public posts depict a profitable, rapidly growing business consistent with scaling talent needs.

Investor Backing & Capital Strength: Successive up-rounds (Series C in 2023 and Series D in 2024) with a marked valuation step-up indicate strong investor conviction and ample capital for expansion. Feedback suggests this funding underpins continued product investment and nationwide scaling.

Market Expansion: The platform reports activity in all 50 states and D.C., rising provider and patient counts, and expansion into Medicare Advantage and Medicaid. Help-center updates and company materials highlight broader coverage and multi‑state credentialing enabling nationwide reach.

Strategic Partnerships: Participation with major insurers (e.g., Aetna, select BCBS plans, Cigna/Evernorth, UnitedHealthcare/Optum) and support from partners like BCBS Massachusetts signal strong payer alignment. These relationships appear to facilitate national scale and access across plan types.

Strong Revenue Growth: Company communications report that ARR more than tripled in 2025 and describe “breakout momentum” supporting scale‑up. These disclosures also note expanded sponsor relationships alongside rising subscription and services revenue.

Market Expansion: Public materials outline added or relocated offices beyond Chicago (e.g., Dallas, New York, Toronto, Bengaluru), with third‑party listings reflecting multiple locations. A steady 2025–2026 update cadence on footprint suggests a broader go‑to‑market presence.

Product Line Growth: Announcements detail the Astradis analytics/AI platform and a new AI‑driven Pricing Suite, with additional industry‑specific capabilities introduced in 2026. Recent case studies for PE‑backed operators indicate continued investment and adoption across use cases.

Strong Revenue Growth: Recent results show strong year-over-year revenue increases, with momentum carrying into the latest quarter and management raising the full-year outlook.

Profitability: FY2026 marked the first full year of positive non-GAAP operating income, with management highlighting meaningful operating-margin expansion and improved unit economics.

Market Expansion: New enterprise wins, a new Boston office, and a pending acquisition in Brazil indicate ongoing geographic and customer expansion.

Product Line Growth: Product launches such as expanded Cedar Intelligence for billing, the Kora AI voice agent, and affordability tools indicate a steady cadence of feature expansion. These additions broaden use cases from post‑visit billing into coverage, affordability, and automated support.

Market Expansion: New deployments and marketplace integrations (e.g., health‑system wins, ambulatory channels, and marketplace distribution) show expanding reach across health systems, medical groups, and practices. Such channels open growth vectors beyond large enterprise hospital deals.

Strategic Partnerships: Partnerships and ecosystem collaborations (e.g., marketplace integrations and communications platforms) support scale and adoption. An acquisition expanding payer–provider workflows further extends platform breadth and go‑to‑market leverage.

Profitability: Reported results show record adjusted operating income with margin expansion, and management increased full‑year adjusted profit targets. This suggests operating leverage is improving alongside growth.

Resilient & Sustainable Growth: Gross profit grew robustly and management raised both near‑term and full‑year gross‑profit outlooks. Cash App and Square delivered continued year‑over‑year gains, reinforcing an upward trajectory.

Innovation-Driven Growth: Leadership attributes momentum to AI‑driven product velocity, including new automation tools in Cash App and for sellers. These initiatives are positioned as contributors to growth and efficiency across the ecosystems.

Investor Backing & Capital Strength: Recently closed a $50 million Series B led by Battery Ventures, bringing total funding to $76 million and adding a new board member. These signals indicate ample runway to scale product and go‑to‑market.

Innovation-Driven Growth: The platform is repositioned as “the operating system for agentic fund management,” layering AI-driven, audit‑grade workflows over deterministic rails. This AI‑forward narrative includes specific performance claims around faster reconciliations and reporting for fund finance teams.

Strong Hiring & Retention: Public signals show a 51–200 employee band, active recruiting for roles such as Senior Manager, People, and a move to a larger NYC office to support growth. These markers are typical of a scaling startup investing in team capacity.

Product Line Growth: The May 2026 launch of Flatiron Telescope, an AI analytics platform built on multi‑country longitudinal oncology data, signals active expansion of the product portfolio. Additional 2026 Panoramic prostate cancer datasets spanning the US, UK, and Germany reinforce new offerings.

Strategic Partnerships: Abbott’s March 2026 integration of its precision oncology testing directly into OncoEMR indicates deeper, EMR‑embedded collaborations at the point of care. Such integrations suggest widening partner‑driven reach in community oncology workflows.

Market Expansion: Company materials describe a larger technical and geographic footprint in 2026, with datasets and platforms spanning the US, UK, Germany, and Japan. New cross‑country datasets (e.g., Panoramic prostate cancer) indicate scaling of international real‑world data assets.

Investor Backing & Capital Strength: Feedback suggests the Blackstone acquisition and references to Enverus as a Blackstone-backed company imply strong access to capital and sponsor support for scaling. Announced financing and valuation signals indicate resources available for continued expansion.

Market Expansion: Feedback suggests acquisitions like Pearl Street Technologies and Spatial Business Systems extend capabilities into power, utilities, and grid design. New offerings like Global Research indicate broader geographic and segment reach.

Product Line Growth: Feedback suggests launches such as Global Research and AI-enabled planning tools expand the platform’s solution set. The company’s newsroom cadence and new features point to an enlarging product footprint.

Strong Market Position & Advantage: Independent analyst recognition as a Leader in The Forrester Wave: Cyber Risk Quantification Solutions (Q2 2025) signals competitive strength and customer traction. Repeated leadership placement suggests durable positioning in its core CRQ niche.

Strategic Partnerships: Named partnerships with BlueVoyant (2025), Dragos (2026), and insurance‑channel offerings via AegisExec/Lloyd’s broaden distribution, data inputs, and relevance to OT and underwriting workflows. These alliances indicate expanding go‑to‑market reach and use‑case breadth.

Product Line Growth: Launches such as BoD Cyber Insights (2025), updated quantification/assessment materials (2025), and CRQ.AI (2026) point to ongoing product development targeted at executive reporting and scenario automation. Packaging and feature expansion align with board‑level buyers and evolving CRQ workflows.

Strong Revenue Growth: Company communications indicate multiple years of 70%+ year-over-year revenue gains, including an over-90% increase in 2024. The firm also reiterated momentum while setting a profitability goal for 2026.

Investor Backing & Capital Strength: An $80M Series E at a $1.5B valuation in June 2026 and a $200M capital raise in 2024 signal sustained investor confidence. Financing and partnership arrangements are framed as enabling scale across banking, payments, liquidity, and credit offerings.

Diversified Revenue Streams: Expansion into credit (e.g., Build Card), subscriptions (Current Max), payments/P2P, paycheck advance, and crypto indicates movement beyond interchange-only monetization. Feedback suggests these additions are intended to lift ARPU and broaden monetization levers.

Strong Revenue Growth: Revenue was reported to have more than quadrupled since the prior 2022 raise, which investors validated with an up-round in December 2023. Continued momentum is evidenced by expanding partnerships and integrations announced into 2024–2026.

Strategic Partnerships: Enterprise relationships with firms like Stifel, Hightower, World Investment Advisors, and Snowden Lane broaden distribution to large advisor networks. Collaborations and integrations (e.g., Orion household rebalancing, 401GO fee debiting, Envestnet connectivity) embed the platform in advisor workflows.

Investor Backing & Capital Strength: A $60M growth investment led by ICONIQ Growth in December 2023 provides runway for hiring and product investment. Characterization of the round as an up-round indicates sustained investor confidence.

Strong Revenue Growth: Management cites nine‑figure annual revenue, record 2025 sales, and ongoing year‑over‑year growth into 2026 in on‑the‑record interviews and media coverage.

Market Expansion: The company entered Canada with its UnKibble line and is extending reach via its largest‑ever brand campaign across TV, billboards, subway, and other above‑the‑line channels.

Product Line Growth: Offerings span fresh‑frozen meals, the air‑dried UnKibble/FreshDry line, and pet wellness add‑ons, enabling broader acquisition angles and higher potential customer value.

Strong Revenue Growth: Multiple signals, including multi‑year FT1000 recognition, recent regional gains, and directionally consistent third‑party revenue scale estimates, indicate sustained expansion. Materials suggest growth continues even if the pace is more measured than earlier years.

Product Line Growth: The launch of a self‑serve platform (rtb.com) and continued moves beyond core enterprise retargeting broaden the offering and expand the addressable market. Evidence points to ongoing product expansion aimed at new customer segments.

Future-Ready Strategy: Active testing and implementation around Chrome’s Privacy Sandbox and participation in industry ecosystems (e.g., Prebid, IAB Tech Lab) show preparation for post‑third‑party‑cookie dynamics. This positioning is presented as a medium‑term growth enabler.